Academic literature on the topic 'Hepatitas C'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hepatitas C.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Hepatitas C"
Masilionis, Tomas, Paulius Vargalis, and Raimondas Kiltinavičius. "VIRUSINĖS C HEPATITO INFEKCIJOS IR 2 TIPO CUKRINIO DIABETO KOMORBIDIŠKUMAS." Health Sciences 30, no. 5 (September 21, 2020): 14–17. http://dx.doi.org/10.35988/sm-hs.2020.106.
Full textNorkienė, Sigutė, Jonas Sąlyga, Vida Jankauskienė, and Eglė Dimaitė. "HEMODIALIZĖS SKYRIUJE DIRBANČIŲ MEDICINOS DARBUOTOJŲ RIZIKOS VEIKSNIŲ IR JŲ ĮTAKOS SVEIKATAI ANALIZĖ." Sveikatos mokslai 24, no. 4 (February 20, 2014): 106–10. http://dx.doi.org/10.5200/sm-hs.2014.076.
Full textViana, Daniel Rodrigues, Nathalia Mundoco Veloso, Osvaldo Carvalho Neto, Nicolas Garcia Papacosta, Gabriel Martins Nunes, and Virgílio Ribeiro Guedes. "Hepatite B e C: diagnóstico e tratamento." Revista de Patologia do Tocantins 4, no. 3 (September 26, 2017): 73. http://dx.doi.org/10.20873/uft.2446-6492.2017v4n3p73.
Full textSalam, Abdul, Bilqis Aslam Baloch, Naseer Khan, Ghulam Sarwar, and Masoom ,. "SEROPREVALENCE OF HBsAg (HBS) AND ANTI-HCV." Professional Medical Journal 21, no. 04 (December 7, 2018): 766–70. http://dx.doi.org/10.29309/tpmj/2014.21.04.2424.
Full textLeite, Juliana Mayara da Silva, Jéssica de Oliveira Inácio, Raissa Silva De Melo Monteiro, Cristiane da Câmara Marques, Vanessa Pinheiro Barreto, and Alexsandra Rodrigues Feijão. "Sociodemographic and clinical characterization of patients with chronic hepatitis C." Enfermería Global 18, no. 3 (June 6, 2019): 157–94. http://dx.doi.org/10.6018/eglobal.18.3.316971.
Full textJain, Ravi, and Ashok Yadav. "Hepatitis B Versus Hepatitis C in Blood Donors." Annals of Applied Bio-Sciences 4, no. 1 (January 2017): A8—A13. http://dx.doi.org/10.21276/aabs.2017.1306.
Full textMaria, Rafael Carvalho de, Joseneide Teixeira Câmara, Maria Edileuza Soares Moura, Felipe Santana e. Silva, and Josemeire da Costa Ximenes. "Analysis of space and epidemiological distribution of hepatitis b and c cases in municipaly maranhão / Análise da distribuição espacial e epidemiológica dos casos de hepatite b e c em município maranhense." Revista de Pesquisa Cuidado é Fundamental Online 13 (September 22, 2021): 1421–27. http://dx.doi.org/10.9789/2175-5361.rpcfo.v13.9702.
Full textLeite Segundo, Airton, Emerson Filipe Nogueira, Patrícia Élida Carvalho, and Maria Sueli Soares. "Avaliação da soroprevalência dos vírus das hepatites B e C em cirurgiões-dentistas." Journal of the Brazilian College of Oral and Maxillofacial Surgery 5, no. 3 (November 20, 2019): 29–33. http://dx.doi.org/10.14436/2358-2782.5.3.029-033.oar.
Full textCONTE, Vinício Paride. "Hepatite crônica por vírus C: Parte 1. Considerações gerais." Arquivos de Gastroenterologia 37, no. 3 (July 2000): 187–93. http://dx.doi.org/10.1590/s0004-28032000000300010.
Full textPayne, E., S. Totten, and C. Archibald. "Surveillance de l'hépatite C au Canada." Relevé des maladies transmissibles au Canada 40, no. 19 (December 18, 2014): 433–41. http://dx.doi.org/10.14745/ccdr.v40i19a01f.
Full textDissertations / Theses on the topic "Hepatitas C"
Pajenčkovskytė, Karolina. "Sergančiųjų lėtiniu virusiniu C hepatitu genotipai." Master's thesis, Lithuanian Academic Libraries Network (LABT), 2004. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2004~D_20040608_165139-44050.
Full textSurgunt, Natalja. "Operacinės slaugytojų susižeidimų adatomis ir kitais aštriais instrumentais rizikos vertinimas." Master's thesis, Lithuanian Academic Libraries Network (LABT), 2014. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2014~D_20140711_084759-08878.
Full textResearch aim: to assess the risk of operating room nurses injuries with needles and other sharp instruments. Research object: operating room nurses injuries with needles and other sharp instruments. Research objectives: 1. To asses frequency, type and reasons of operating room nurses injuries with needles and other sharp instruments. 2. To analyse influencing causes for safe operating room environment. 3. To analyse the operating room nurses attitudes towards registration and reporting of injuries inflicted by needles and other sharp instruments. Research methodology: Research was done in January–April 2013 in Vilnius and Kaunas 3rd level hospitals. For this research two types of questionnaires, written by German scientist Dr. Sabine Wicker, were used: „Incidental Injury“ („Ein stich Stecktan“) and „Minimizing the danger of infection – prevent the needle puncture“ (,,Infektionsrisiken senken – Nadelstichverletzungen vermeiden“). Questionnaires were translated to Lithuanian language. There were 200 questionnaires distributed in total, 185 of them were returned and 10 were not fully answered. 175 fully answered questionnaires were used for statistical analysis. SPSS 17.0 and Microsoft Excel programs were used for statistical data analysis. Statistical data meaningfulness was verified by chi quadrant (χ2) criteria and statistical meaningfulness. Data difference is meaningful when p<0,05. Factor analysis method was used for the research. Results and conclusions: During the... [to full text]
Petrenkienė, Vitalija. "Ligonių, sergančių lėtiniu hepatitu c, ligos raiškos ypatumai, gydymo interferonu a–2b ir ribavirinu efekto įvertinimas ir požymių, lemiančių gydymo rezultatus, nustatymas." Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2005. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2005~D_20050606_220244-71931.
Full textValentienė, Jolanta. "Virusinių hepatitų A, B, ir C serologinių žymenų paplitimas neatlygintinų kraujo donorų populiacijoje 2010-2011 m." Master's thesis, Lithuanian Academic Libraries Network (LABT), 2014. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2012~D_20140630_173316-42743.
Full textAim: to describe epidemiology of the viral hepatitis A, B, C, HIV and other sexually transmitted infections (STD) and to estimate prevalence of HAV, HBV, HCV infections among first time non-remunerated blood donors population. Methodology: The study received approval from Vilnius Regional Biomedical Research Ethics Committee. First time non-remunerated blood donors participated in anonymous questionnaire survey in NGO National Blood Center. For anti-HAV, anti-HCV, anti-HBs, anti-Hbcor and HBsAg detection was used immunoenzyme method and for HBV DNR ir HCV RNR - nucleic acid amplification test. The Mantel trend test and linear regression method was used to evaluate the trend of viral hepatitis, HIV and other sexually transmitted infections. The prevalence of viral hepatitis serological markers was expressed in percentage points, the precision was evaluated at the confidence intervals (CI) of 95%, the comparison of categorical data was made using χ2 test and Fisher‘s exact test. For data analysis the following tests were used: for the risk factors – binary logistic regression; goodness of fit – Hosmer-Lemeshow χ2 test; Cox and Snell R Square, Classification Table. The statistical significance level p ≤ 0.05. Results: A total of 200 respondents haven been interviewed. Only 188 first time non-remunerated blood donors were selected for further analysis. Respondents minimum of age was 18 and maximum - 52 (Mean=22,6; Med=20,0), 47,9 % (n=90) of them were males, 52,1... [to full text]
Bakaitis, Paulius. "Sergančiųjų lėtiniu virusiniu C hepatitu demografinių rizikos faktorių bei biocheminių ir histologinių ligos charakteristikų statistinė analizė." Master's thesis, Lithuanian Academic Libraries Network (LABT), 2014. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2006~D_20140702_194115-67371.
Full textThe aim of work was to examine patients with hepatitis C, i.e. to find out specialities of disease. Statistical analysis was carried out. The results are as follows. There was discovered direct impact of alcohol to histological and biochemical indicators as well as changes influenced by cirrhosis. The relationships among histological activity index and biochemical blood indicators was also explored. These are the main results however other indicators were also of high interest.
Valente, Vanderleia Barbaro. "Estudo da distribuição dos marcadores sorológicos das hepatites B e C entre doadores de sangue do Hemocentro de Ribeirão Preto, SP." Universidade de São Paulo, 2002. http://www.teses.usp.br/teses/disponiveis/17/17139/tde-29052003-193717/.
Full textThis study, which involved all blood donors (25.891) that attended the Blood Center of Ribeirão Preto for the first time from June 1996 to June 2001 had the following objectives: 1) To study the positiveness for hepatitis B and C serologic markers in donors screening tests. 2) To analyze the flow of positive donors for hepatitis B and C markers to the Hepatitis Ambulatory (HA) in the Clinical Hospital of the Faculty of Medicine of Ribeirão Preto of the University of São Paulo. 3) To estimate the predominance of present or former infection by hepatitis B and C viruses among donors, by analyzing results of screening tests that confirm these diseases. 4) To evaluate the importance of determining the glutamic-piruvic transaminase (GTP) as an indirect marker of infection by hepatitis B and C viruses. Registered data from the Blood Center as well as from the Epidemiological Surveillance Nucleus (ESN) and HA were used with the purpose of collecting information about donors, type of donation and results in serologic screening tests (HBsAg, anti-HBc, anti-HCV, GTP, anti-HIV, anti-HTLV, Chagas disease and syphilis). In addition, a study was performed on the results in repetition tests that took place in the Blood Center of positive donors for hepatitis B and C markers in serologic tests as well as on their attendance at the ESN and the confirmation in the HA of the results for these markers. The population of donors was composed in its majority by men (83,6%) and individuals from 26 to 45 year-old (64,0%). Linked donations predominated (85,4%), and the greatest reasons for donation arose from solicitation and stimulus coming from family and friends. The value of prevalence in serologic screening tests was 0,63% (IC95%: 0,54 0,72) for HBsAg and 1,15% (IC95%: 1,02 1,28) for anti-HCV. The total of positive donors that should have been evaluated in the HA suffered a loss of 55,5% among the suspects of having hepatitis B and of 58,7% among the suspects of having hepatitis C, reaching a total of 266 donors lost during follow-up. The value of prevalence in confirmatory tests was 0,22% (IC95%: 0,16 0,28) for hepatitis B and 0,31% (IC95%: 0,24 0,38) for hepatitis C. The copositiveness between GPT and hepatitis markers in serologic screening tests was 8.8% for hepatitis C virus and 0.5% for hepatitis B virus, indicating that determination of this enzyme is not helpful in selection of donors in blood banks.
Silva, Filho Hermes Pedreira da. "Estudo Molecular dos Vírus B e C das Hepatites nas Regiões Norte e Nordeste do Brasil." reponame:Repositório Institucional da FIOCRUZ, 2010. https://www.arca.fiocruz.br/handle/icict/4219.
Full textMade available in DSpace on 2012-07-19T21:21:54Z (GMT). No. of bitstreams: 1 Hermes Pedreira EStudo molecular dos vírus B e C...2010.pdf: 5589974 bytes, checksum: b86706272dbb22d0d349edae7d641ce1 (MD5) Previous issue date: 2010
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, Bahia, Brasil
Infecções pelos vírus B e C das hepatites constituem um significante problema de saúde pública em todo mundo. Mais de 350 milhões de pessoas estão cronicamente infectadas pelo VHB e 170 milhões pelo VHC. No Brasil, a prevalência de pessoas infectadas pelo VHB varia de baixa endemicidade (<2%) até alta, (>7%), e estima-se que 1,5% da população esteja infectada pelo VHC (WHO). Estudos recentes tem demonstrado consideráveis variações entre os isolados do VHB, confirmando a diversidade de genótipos do vírus circulantes e o surgimento de mutações no genoma viral que podem ter impacto na resposta terapêutica e imune. Informações sobre a diversidade genética do VHB serão de grande valor para determinar fatores de risco associados a disseminação do vírus e auxiliar na adoção de medidas de prevenção e terapêutica. A infecção pelo VHC tornou-se um sério problema de saude pública desde que não existe uma vacina disponível e o tratamento é extremamente caro para os órgãos públicos como desgastante para o paciente. Este trabalho utilizou as ferramentas moleculares e de epidemiologia no estudo destes vírus para caracterizar molecularmente os vírus B e C das hepatites nas Regiões Norte e Nordeste, particularmente na Bahia, através de sequenciamento de DNA e análises filogenéticas. Amostras de pacientes provenientes da Bahia, Acre, Rondonia, Amazonas, Maranhão e Tocantins foram analisadas. As amostras foram oriundas de outros estudos e de centros de referência para tratamento das hepatites, sendo avaliadas 635 amostras para o VHC e 335 de VHB. Sequencias das regiões pré-S/S e pré- Core/Core do VHB e NS5b, 5UTR, E1 e Core do VHC foram utilizadas para classificação genotípica e análise filogenetica. Os genótipos mais frequentes para o VHB foram A (57%), D (10%) e F(33%) na Bahia e nas amostras da região Norte. Nós encontramos em nosso estudo 55,6% de pacientes co-infectados com VHB/Delta. Não foi possível estabelecer uma ligação genótipo específico com a evolução da infecção, e determinar a presença de mutantes relacionados à resposta terapêutica e ao escape imunológico. Com relação ao VHC, a subtipagem dos isolados foi realizada através do sequenciamento da região NS5b e 5UTR (n=230). Os sub-genótipos mais frequentes foram 1a(45,6%), 1b (46,9%), 3a (6,5%) e 2a/b(0,8%). As regiões E1 e Core também foram sequenciadas e no futuro serão utilizadas para avaliar possiveis mutações. O presente estudo mostra que a aplicação de protocolos de sequenciamento, bioinformática e filogenia são indispensáveis para a compreensão da epidemiologia molecular dos vírus das hepatites.
Infections with hepatitis B and C viruses constitute a significant public health problem worldwide. More than 350 million people are chronically infected with HBV and 170 million by HCV. In Brazil, HBV remains endemic despite widespread vaccination with prevalence of infection ranging from (<2%) low endemicity, until high (>7%) in different regions. Prevalence of HCV infection in Brazil has been estimated at 1.5%. Recent studies have shown considerable genetic variation among HBV isolates, confirming the diversity of circulating genotypes of the virus and the emergence of mutations in the viral genome that may impact on therapeutic and immune response. Information on the genetic diversity of HBV is useful for molecular epidemiology to determine risk factors associated with the spread of the virus and to inform prevention strategies and for monitoring therapy. Because there is no vaccine available to prevent HCV infection and treatment is extremely expensive for public agencies, HCV is an emerging public health problem. The treatment efficiency is directly related to viral genotype. In this study molecular epidemiology tools were used to characterize HBV and HCV in the North and Northeast, particularly in Bahia, through DNA sequencing and phylogenetic analysis. Samples from Bahia, Acre, Rondônia, Amazonas, Maranhão and Tocantins were analyzed. The samples were collected in collaboration with other studies and centers of references for hepatitis treatments. 635 samples from HCV infected patients and 335 samples from HBV infected were evaluated. Sequences of the regions pre-S / S, HBV core / pre-core, NS5B, 5UTR, HCV Core and E1 were used for genotypic classification and phylogenetic analysis. The most frequent HBV genotypes were A (57%), D (10%) and F (33%) in Bahia and in the samples from the North region. Fifty five percent of the patients from Rondônia were coinfected with HBV and HDV. In this study, we were unable to establish a connection with the particular genotype evolution of the infection and determine the presence of mutants related to therapeutic response and immune escape. In the North region co-infection with HBV genotype F and D virus is strongly associated with poor outcome of the disease as informed by the physicians and literature. Regarding HCV, the subtyping of isolates was performed by sequencing the NS5B region and 5UTR (n=230). The sub-genotypes more frequent were 1a (45.6%), 1b (46.9%), 3a (6.5%) and 2a / b (0.8%). The Core and E1 regions were also sequenced and in the future could be used to evaluate possible mutations. This study shows that the implementation of protocols for sequencing, bioinformatics and phylogenetic are essential for understanding the molecular epidemiology of hepatitis.
Machado, Danusa de Almeida. "Qualidade de vida e morbidade psicológica de pacientes portadores de hepatite C em tratamento com interferon peguilado e ribavirina /." Botucatu, 2009. http://hdl.handle.net/11449/98430.
Full textAbstract: This study aimed at describing socio-demographic, psychosocial and clinical characteristics as well as quality of life indexes, occurrence of common mental disorder and depressive symptoms of patients with chronic hepatitis C undergoing treatment at the Viral Hepatitis Outpatient Unit of the Botucatu Medical School - UNESP, at three different moments of their treatment with Peguilated Interferon and Ribavirin: immediately before treatment, 12 and 24 weeks after its introduction. The association of socio-demographic and clinical variables as well as those for common mental disorder (CMD), depression symptoms and form of treatment with quality-of-life (QL) indexes was evaluated at the three studied moments. The association of such variables with test results indicating virological response to treatment (detection of the hepatitis C virus RNA by the PCR method) was also investigated. Method: A convenience sample was established, and 82 patients were studied in a cross-sectional and follow-up investigation. Forty-six patients were followed 3 and 6 months after the beginning of treatment. A structured questionnaire was used to investigate socio-demographic and clinical aspects. Depression symptoms were evaluated by the Beck Depression Inventory (BDI). The Self Reporting Questionnaire (SRQ) was utilized to evaluate common mental disorder, and harmful use of alcohol was evaluated by the Alcohol Use Disorders Identification Test (AUDIT). Quality of life was assessed by the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36). The study of the associations between categorial variables was performed by the chi-square test (or Fisher, if adequate). The Mann-Whitney and Kruskal Wallis tests were used to compare the distribution of various domains of SF-36. McNemar's Exact Test was used for category variables to compare the data at the subsequent moments, and Friedman's Test was... (Complete abstract click electronic access below)
Orientador: Ana Teresa de Abreu Ramos-Cerqueira
Coorientador: Giovanni Faria Silva
Banca: Fani Eta Korn Malerbi
Banca: Carlos Antonio Caramori
Mestre
Silva, Edvaldo Ferreira da. "Prevalência de marcadores sorológicos das hepatites A e B em pacientes com hepatite C crônica atendidos no ambulatório de hepatites do serviço de Gastroenterologia Clínica do Hospital das Clínicas da Faculdade de Medicina da Universidade." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/5/5168/tde-04022015-153903/.
Full textBackground and Aims: Patients with chronic HCV and superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) have higher morbidity and mortality when compared with those without HCV. For this reason, HAV and HBV active immunization has become mandatory in this population and hence their serological markers must be determined. The aim of this study was to evaluate the prevalence of serological markers of HAV and HBV infection in patients with chronic HCV. Methods: 1.000 chronic HCV infected patients at the University of Sao Paulo School of Medicine outpatient Liver Clinic were evaluated for the prevalence of serological markers of HAV and HBV infection. Results: Anti-HAV IgG was positive in 923 of 1000 patients (92.3%). When stratified by age, the anti-HAV IgG was found in 61% of patients between 20-29 years, 70% between 30-39 years, 85% between 40-49 years, 94% between 50-59 years, and 99% over 60 years of age. Anti-HBc IgG was positive in 244 patients (24%). Stratified by age, anti-HBc IgG was found in 4.3% of patients between 20-29 years, 17% between 30-39 years, 21% between 40 -49 years, 24% between 50-59 years, and 28% of patients over 60 years of age. Of the 244 anti-HBc IgG positive patients, 0.8% were also HBsAg positive, 8.5% were anti-HBc IgG isolated and 16% were also anti-HBs positive. Conclusions: The prevalence of anti-HAV IgG was similar to the general population in the city of São Paulo. However, anti-HBc IgG was higher in our chronic HCV patients, when compared historically to the general population of western countries, suggesting similar risk factors for HBV and HCV acquisition, so emphasizing the importance of immunization programs in this population. Keywords: Hepatitis C, Chronic; Hepatitis C; Hepacivirus, Prevalence; Hepatitis A; Hepatitis B Título: Prevalência de Marcadores Sorológicos das Hepatites A e B em Pacientes com Hepatite C Crônica atendidos no Ambulatório de Hepatites do Serviço de Gastroenterologia Clínica do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP Background and Aims: Patients with chronic HCV and superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) have higher morbidity and mortality when compared with those without HCV. For this reason, HAV and HBV active immunization has become mandatory in this population and hence their serological markers must be determined. The aim of this study was to evaluate the prevalence of serological markers of HAV and HBV infection in patients with chronic HCV. Methods: 1.000 chronic HCV infected patients at the University of Sao Paulo School of Medicine outpatient Liver Clinic were evaluated for the prevalence of serological markers of HAV and HBV infection. Results: Anti-HAV IgG was positive in 923 of 1000 patients (92.3%). When stratified by age, the anti-HAV IgG was found in 61% of patients between 20-29 years, 70% between 30-39 years, 85% between 40-49 years, 94% between 50-59 years, and 99% over 60 years of age. Anti-HBc IgG was positive in 244 patients (24%). Stratified by age, anti-HBc IgG was found in 4.3% of patients between 20-29 years, 17% between 30-39 years, 21% between 40 -49 years, 24% between 50-59 years, and 28% of patients over 60 years of age. Of the 244 anti-HBc IgG positive patients, 0.8% were also HBsAg positive, 8.5% were anti-HBc IgG isolated and 16% were also anti-HBs positive. Conclusions: The prevalence of anti-HAV IgG was similar to the general population in the city of São Paulo. However, anti-HBc IgG was higher in our chronic HCV patients, when compared historically to the general population of western countries, suggesting similar risk factors for HBV and HCV acquisition, so emphasizing the importance of immunization programs in this population
Moraes, Camila Fernanda Verdichio de [UNESP]. "Antígeno plaquetários humanos (HPA) em portadores do vívus da hepatite c (HCV)." Universidade Estadual Paulista (UNESP), 2009. http://hdl.handle.net/11449/102625.
Full textCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
A Hepatite C é uma das principais causas de doença crônica hepática. A combinação entre o interferon peguilado e a ribavirina tem sido considerado o padrão-ouro de tratamento para Hepatite C. A resposta ao tratamento vem sendo associada a fatores ambientais, do vírus e também do paciente, tais como polimorfismos genéticos dos antígenos leucocitários humanos (HLA), da interleucina-10 e do fator de necrose tumoral-a. Plaquetas possuem em suas membranas glicoproteínas que expressam segmentos protéicos polimórficos, os quais são chamados de antígenos plaquetários humanos (HPA). Os sistemas HPA-1, -3, -4 e -5 residem em integrinas, proteínas que possuem interações com interferon. O objetivo desse estudo foi avaliar a associação entre freqüência dos HPA-1, -3, -4 e -5 e a resposta ao tratamento, em 138 pacientes tratados para Hepatite C. A genotipagem dos HPA-1, -3 e -4 foi realizada pela técnica de PCR-SSP e do HPA-5 pela PCR-RFLP. A genotipagem do HCV foi realizada através do Kit comercial INNO-LiPA® v.1.0 (Innogenetics, Ghent, Belgium), segundo as instruções do fabricante. Os pacientes foram divididos em grupos e subgrupos de acordo com o esquema terapêutico, a resposta ao tratamento e o genótipo do HCV. Os pacientes que possuíam o genótipo do HCV não-1 e que foram tratados com IFN-a+RBV, com falha terapêutica, apresentaram uma diferença estatística significante (p<0.05) nas freqüências alélicas e genotípicas do sistema HPA-3, com aumento do alelo 3b. O sistema HPA-3 está localizado em uma integrina que se liga a fibronectina, um receptor de interferon. Nesse contexto, a alteração conformacional glicoprotéica decorrente da presença do alelo HPA-3b, poderia estar associada à falha ao tratamento com IFN-a+RBV em pacientes portadores de genótipo viral não-1.
Hepatic fibrosis leading cirrhosis in 20 to 30% of patients with chronic hepatitis C virus (HCV) infection. Rapid progression to fibrosis has been related to environmental, viral and host factors. However, genetic polymorphisms have recently been associated with this progression, including the expression of integrins. Platelet membrane glycoproteins express several polymorphic antigenic determinants on their surface, which are called human platelet antigens (HPA). HPA-1, -3, -4 and -5 reside in integrins. The association between HPA antigens and stage of fibrosis can determine if HPA is related to progression of fibrosis. Thus, the goal of this study was to determine the association between the HPA-1, -3, -4 and -5 and the liver fibrosis stage in 175 HCV-infected patients. HPA-1, -3 and -4 genotyping was performed by PCR-SSP and, HPA-5 by PCR-RFLP. Fibrosis progression was evaluated using the METAVIR scoring system. There were no significant differences (p>0.05) in allelic and genotypic frequency distribution of HPA-1, -3 and -5, residing in integrins.
Books on the topic "Hepatitas C"
Askari, Fred K. Hepatitis C, the silent epidemic: The authoritative guide. New York: Plenum Trade, 1999.
Find full textAskari, Fred K. Hepatitis C, the silent epidemic: The authoritative guide. Cambridge, Mass: Perseus, 2001.
Find full textCanada. Library of Parliament. Parliamentary Research Branch. Hepatitis C. Ottawa: Library of Parliament, 1999.
Find full textOzaras, Resat, and Dominique Salmon-Ceron, eds. Viral Hepatitis: Chronic Hepatitis C. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4.
Full textLau, Johnson Y. N. Hepatitis C Protocols. New Jersey: Humana Press, 1998. http://dx.doi.org/10.1385/0896035212.
Full textBook chapters on the topic "Hepatitas C"
Arends, Joop E., Maria Cristina Leoni, and Dominique Salmon. "Acute Hepatitis C." In Viral Hepatitis: Acute Hepatitis, 45–65. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03535-8_4.
Full textArends, Joop E., Maria Cristina Leoni, and Dominique Salmon-Ceron. "Acute Hepatitis C." In Viral Hepatitis: Chronic Hepatitis C, 197–217. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_11.
Full textArends, Joop E., Maria Cristina Leoni, and Dominique Salmon. "Correction to: Acute Hepatitis C." In Viral Hepatitis: Acute Hepatitis, C1—C2. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03535-8_7.
Full textBendinelli, Mauro, Maria Linda Vatteroni, Fabrizio Maggi, and Mauro Pistello. "Hepatitis C Virus." In Viral Hepatitis, 65–127. Totowa, NJ: Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-702-4_4.
Full textKorn, Klaus. "Hepatitis C." In S2k-Leitlinie - Labordiagnostik schwangerschaftsrelevanter Virusinfektionen, 133–43. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43481-9_13.
Full textMondelli, Mario U., Stefania Varchetta, and Francesco Negro. "Hepatitis C." In Liver Immunology, 207–30. Cham: Springer International Publishing, 2013. http://dx.doi.org/10.1007/978-3-319-02096-9_15.
Full textCiesek, Sandra. "Hepatitis C." In Praxis der Hepatologie, 57–61. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-642-41620-0_132.
Full textCiesek, Sandra. "Hepatitis C." In Praxis der Hepatologie, 57–61. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-642-41620-0_9.
Full textMylonas, Ioannis. "Hepatitis C." In Sexuell übertragbare Erkrankungen, 199–207. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-642-37928-4_26.
Full textDusheiko, Geoffrey. "Hepatitis C." In Sherlock's Diseases of the Liver and Biliary System, 436–67. Chichester, UK: John Wiley & Sons, Ltd, 2018. http://dx.doi.org/10.1002/9781119237662.ch23.
Full textConference papers on the topic "Hepatitas C"
Prasetia Nurwidda, Arvi Dian, Poernomo Boedi Setiawan, Iswan Abbas Nusi, Herry Purbayu, Titong Sugihartono, Ummi Maimunah, Ulfa Kholili, et al. "Thrombocytopenia in Chronic Hepatitis C." In Surabaya International Physiology Seminar. SCITEPRESS - Science and Technology Publications, 2017. http://dx.doi.org/10.5220/0007340404460452.
Full textCoelho, Henrique, and Fernanda Canedo. "Hepatite pelo vírus C." In XVI Semana Brasileira do Aparelho Digestivo. Editora Manole, 2017. http://dx.doi.org/10.22288/9788520456507000017.
Full textEid, Fatma Elzahraa, Haitham Elmarakeby, Lenwood Heath, and Mahmoud ElHefnawi. "Human microRNAs targeting hepatitis C virus." In 2014 Middle East Conference on Biomedical Engineering (MECBME). IEEE, 2014. http://dx.doi.org/10.1109/mecbme.2014.6783236.
Full textChawathe, Sudarshan S. "Diagnostic Classification Using Hepatitis C Tests." In 2020 IEEE International IOT, Electronics and Mechatronics Conference (IEMTRONICS). IEEE, 2020. http://dx.doi.org/10.1109/iemtronics51293.2020.9216446.
Full textPaschoini, MC, LN Resende, MM Mendonça, GPM Gomide, and JU Ribeiro. "P3.181 Hepatitis c: challenging modern obstetrics." In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.416.
Full textKchir, H., D. KAFFEL, H. Dabbebi, D. ISSAOUI, H. Sahli, W. Hamdi, M. Elleuch, M. M. Kchir, R. Debbeche, and N. Maamouri. "AB1049 Rheumatological manifestations during chronic hepatitis c." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5886.
Full textGür, A., M. Karakoç, MF Geyik, K. Nas, R. Çevik, AJ Saraç, S. Em, and F. Erdogan. "SAT0135 Association between hepatitis c virus antibody, hepatitis b virus antigen and fibromiyalgia." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.594.
Full textKhan, Asma, Azeema Sadia, Sohaib Ahmed, Huma Tabassum, and M. Shahid Khan. "HEPO: The hepatitis ontology for abductive medical diagnostic systems." In 2017 International Conference on Communication, Computing and Digital Systems (C-CODE). IEEE, 2017. http://dx.doi.org/10.1109/c-code.2017.7918941.
Full textGarcia-Guix, Alexandra, Lina Oviedo, Rosa Sauras-Quetcuti, Gerard Mateu-Codina, Marta Nayach, Rebeca Alayon-Santana, Laura Oliva, and Marta Torrens. "Modelo de microeliminación de la Hepatitis C. Cascada de cuidados para la hepatitis C del CAS Santa Coloma - Barcelona." In 22° Congreso de la Sociedad Española de Patología Dual (SEPD) 2020. SEPD, 2020. http://dx.doi.org/10.17579/sepd2020o024.
Full textSchlevogt, B., K. Böker, S. Mauss, H. Klinker, R. Heyne, R. Link, KG Simon, et al. "Weight gain after interferon-free clearance of chronic hepatitis C – Results from the German Hepatitis C-Registry (DHC-R)." In Viszeralmedizin 2019. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1695343.
Full textReports on the topic "Hepatitas C"
Kuypers, Marshall A., Gregory Joseph Lambert, Thomas W. Moore, Glass, Robert John,, Patrick D. Finley, David Ross, and Maggie Chartier. Modeling Hepatitis C treatment policy. Office of Scientific and Technical Information (OSTI), September 2013. http://dx.doi.org/10.2172/1096266.
Full textSjogren, Maria H., and Kent Holtzmuller. Hepatitis C Virus Infection: Mechanism of Disease Progression. Fort Belvoir, VA: Defense Technical Information Center, October 2001. http://dx.doi.org/10.21236/ada406083.
Full textSjogren, Maria H. Hepatitis C. Virus Infection: Mechanism of Disease Progression. Fort Belvoir, VA: Defense Technical Information Center, October 2004. http://dx.doi.org/10.21236/ada433067.
Full textSjogren, Maria H., and Brooke Huntley. Hepatitis C. Virus Infection: Mechanisms of Disease Progression. Fort Belvoir, VA: Defense Technical Information Center, October 2007. http://dx.doi.org/10.21236/ada477987.
Full textKoizumi, Yoshiki, Syo Nakajim, Hirofumi Ohash, Yasuhito Tanaka, Takaji Wakita, Alan S. Perelson, Shingo Iwami, and Koichi Watashi. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Office of Scientific and Technical Information (OSTI), March 2016. http://dx.doi.org/10.2172/1242919.
Full textNguyen, Tung, Mandana Khalili, Janice Tsoh, Judith Walsh, Elizabeth Goldman, Arcadi Kolchak, Ginny Gildengorin, Ching Wong, and Ivy Lau. Comparing Ways to Increase Hepatitis B and C Screening Among Asian Americans. Patient-Centered Outcomes Research Institute® (PCORI), March 2020. http://dx.doi.org/10.25302/02.2020.ad.12114615.
Full textMcGlynn, Elizabeth, John Adams, Jason Kramer, Amandeep Sahota, Michael Silverberg, Elizabeth Shenkman, and David Nelson. Assessing the Safety of Direct-Acting Antivirals for Hepatitis C—A PCORnet Study. Patient-Centered Outcomes Research Institute (PCORI), June 2020. http://dx.doi.org/10.25302/06.2020.ri.rcr1000.
Full textBuresh, Christopher. The Opioid Epidemic in Iowa and the Connection to Hepatitis C and HIV Outbreaks. Iowa City, Iowa: University of Iowa Public Policy Center, January 2019. http://dx.doi.org/10.17077/rep.001111.
Full textHoltzmuller, Kent. Utilization of Telemedicine for Evaluation and Treatment of Hepatitis C Patients in Military Health Clinics. Fort Belvoir, VA: Defense Technical Information Center, October 2001. http://dx.doi.org/10.21236/ada396498.
Full textMartinez-Chantar, Malu. Especial Premio Nobel de Medicina 2020: La ciencia vence al virus de la hepatitis C. Sociedad Española de Bioquímica y Biología Molecular, October 2020. http://dx.doi.org/10.18567/sebbmdiv_rpc.2020.10.1.
Full text